Incyte Corporation has received positive feedback from the European Medicines Agency’s expert panel for an expanded use of its cancer treatment, Zynyz (retifanlimab).
EMA Panel Backs New Indication
On Friday, Incyte announced that the EMA’s Committee for Medicinal Products for Human Use endorsed a new indication for Zynyz, a therapy developed in partnership with MacroGenics. This immunotherapy targets gastrointestinal tract (GIT) cancers, offering potential benefits for patients with specific tumor types.
Details of the Endorsement
The committee’s recommendation supports adding the GIT indication to Zynyz’s label, following successful clinical evaluations. Zynyz, an anti-PD-1 monoclonal antibody, inhibits immune checkpoints to enhance the body’s response against cancer cells. Incyte markets the drug in collaboration with MacroGenics, leveraging their combined expertise in oncology.
This development aligns with ongoing efforts to broaden Zynyz’s applications across various solid tumors. The EMA’s endorsement paves the way for formal approval, which could expand treatment options in Europe for patients facing advanced GIT malignancies.
Incyte’s stock (INCY) and MacroGenics’ (MGNX) shares may see movement as investors assess the impact on future revenues and market positioning in the competitive cancer therapy landscape.
